Caring for heavily pretreated @entity1 with @entity0 ( @entity0 ): @entity3003 ( XXXX ) - gemcitabine ( @entity8178 ) combination is effective and well tolerate.

@entity1 @entity137 @entity6023 @entity8178 @entity0 @entity882 @entity417 @entity3003 @entity5948 @entity1398
UNASSIGNED: 724 Background: @entity1 (pts) with @entity0 often receive intensive chemotherapy to halt disease progression. Subsequent treatment choices are thus complex due to cumulative @entity137 of previous therapies, to paucity of effective cytotoxic regimens with a low @entity137 burden, and to compromised performance status. METHODS: A combination of @entity3003 (AUC4, Calvert) plus @entity8178 (1250 mg/m(2) Days 1 _ 8, than reduced to 1000 mg/m(2) ) was given to 28 pts with @entity0 (median age: 50 yrs, range: 31-72; PS 0-1/2: 25/3). All @entity1 previously received chemotherapy for metastatic disease, 21 had >=  3 chemotherapy regimens; 11 pts had disease resistant to both @entity5948 and @entity6023 . RESULTS: After the first 4 pts were treated, @entity8178 -dose was reduced from 1250 to 1000 mg/m(2) because of limiting haematological @entity137 on day 1 or 8, requiring treatment delay/omission: @entity1398 G3 (2 pt) / G4 (1 pt), @entity882 G4 (1 pt), @entity417 G3 (1 pt). After @entity8178 dose-reduction, we observed G3-4 @entity882 (21%,) and @entity1398 (50%), with 1 episode of @entity1398 not requiring hospitalisation. Subjective @entity137 was mild, without non-haematolgical G3-4 @entity137 but G3 skin-reaction (3 pts). Partial responses were observed in 5/23 pts valuable (22%); stable disease and disease progression in 7 and 12 pts, respectively. Two @entity1 with partial responses and 2 with disease stabilisation were observed in the 11 pts resistant to both @entity6023 and @entity5948 . CONCLUSIONS: This regimen is effective and well-tolerated and might be considered a reasonable treatment option for heavily pretreated @entity1 . No significant financial relationships to disclose.
